Simple and Practical Mental Health

The BEST resource for mental health clinicians

  • *MENUS*
  • RESOURCES
    • Side effect handouts
    • Patient handouts: Main page
    • How to find treatment resources
    • Rating scales and questionnaires (Main Menu)
    • BEST books
    • BEST apps/ websites
  • NEWS
  • QUESTIONS?
  • DAILY EMAILS
  • FAQ
  • REVIEWS
  • LOG IN
  • JOIN

Extended-Release Olanzapine (Zyprexa Relprevv®): Basic Information

Extended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication.


FDA-approved indications

Schizophrenia


Dosage forms and strengths

Powder for suspension (for IM use only): 210 mg/vial, 300 mg/vial, and 405 mg/vial


Dosage

Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses

A. First 8 weeks of treatment

a) Target oral dose 10 mg/day: 210 mg/2 weeks or 405 mg/4 weeks

b) Target oral dose 15 mg/day: 300 mg/2 weeks

c) Target oral dose 20 mg/day: 300 mg/2 weeks

B. Maintenance dose after 8 weeks

a) Target oral dose 10 mg/day: 150 mg/2 weeks or 300 mg/4 weeks

b) Target oral dose 15 mg/day: 210 mg/2 weeks or 405 mg/4 weeks

c) Target oral dose 20 mg/day: 300 mg/2 weeks

Note: Zyprexa Relprevv is not approved for the treatment of dementia related psychosis in elderly due to increased risk of death and cerebrovascular accidents.


General Instructions

1. Zyprexa Relprevv® is intended for deep intramuscular gluteal injection only and should not be administered intravenously or subcutaneously.

2. Establish tolerability with oral olanzapine prior to initiating treatment.

3. Must be suspended only in the diluent provided in the convenience kit.

4. Use in specific populations (including renal and hepatic impaired, and pediatric population) has not been studied.


Important! Please refer to the full Prescribing Information (see link below) before prescribing this medication.


Related Pages

Aripiprazole (Abilify Maintena®)

Aripiprazole lauroxil (Aristada®)

Paliperidone palmitate (Invega Sustenna®)

Paliperidone palmitate 3-month (Invega Trinza®)

Risperidone long-acting injection (Risperdal Consta®)

Long-Acting Injectable Antipsychotics

Monitoring patients who are on an antipsychotic


References

Prescribing Information Extended Release Olanzapine (Zyprexa Relprevv®)


Copyright 2016, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.

Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other lay persons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter

Copyright 2016 to 2025: Simple and Practical Medical Education, LLC. All rights reserved.